Background
Materials and methods
Study strategy
Inclusion and exclusion criteria
Data extraction
Quality assessment
Statistical analysis
Results
Eligible studies and their characteristics
Study (Author and year) | Country | size | Tumor type | Sample type | Method (antibody data) | Negative control | Expression location | Cut-off value: (intention) or (IPS = x * y) | High expression ratio: n/N (%) | Follow-up time: mean (min–max) (mon) | Survival outcome | Conclusion (UA/MA) | Multivariate analysis | HR extraction | NOS score |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Yoshida et al. 2017 (I) [14] | Japan | 79 | PDAC | ac (Ca) Startle (St) | IHC (M, Merck Millipore) | NT + NP | NR | 50% | Ca: 54/79 (68%) St: 49/79 (62%) | NR | OS; RFS OS; RFS | NS; NS; NS; P | No | KM plot | 8 |
Zhan et al. 2015 [15] | China | 31 | PDAC | ac | IHC (Millipore) | PBS | NR | 50% | 15/31 (48%) | 47 (3–73) | OS | P | No | P-value | 7 |
Mahawithitwong et al. 2013 [16] | Japan | 95 | PDAC | sf | IHC (R, Protein TechGroup, 1:100) | NR | NR | (4 * 3) 4/12 | 34/95 (64.2%) | 24 (3–136); 14 (0–136) | OS; DFS | P/NS; P/− | Yes | Cox, P-value | 7 |
Cao et al. 2015 (II) [17] | China | 110 | ESCC | scc | IHC (M, Origen,1:50) | NR | C + N | (3 * 4) NR | 34/65 (52%) | 36.5 (0–148.7) | OS; DFS | −/P; −/P | Yes | Cox | 6 |
Cao et al. 2015 (III) [17] | China | 147 | ESCC | scc | IHC (M, Origen,1:50) | NR | C + N | (3 * 4) NR | 20/64 (31%) | 28.8 (27–72) | OS; DFS | P; P | Yes | Cox | 6 |
Wu et al. 2017 [18] | China | 203 | BC | sf | IHC (M, Santa Cruz, 1:500) | PBS | NR | (3 * 4) 6/12 | 109/203 (54%) | 64 (49–78) | OS; CSS; DFS | P/P; P/−; P/− | Yes | Cox | 6 |
Papachristou et al. 2008 [19] | Greece etc. | 60 | CHS | sf | IHC (M, homemade, 1/50) | TBS | C | 33% | 51/60 (85%) | 67.9 (40.9, 2–180) | OS | P | No | P-value | 8 |
Ge et al. 2015 [20] | China | 72 | HCC | ac | IHC (R, ab152106, 1:100) | PBS | NR | (4 * 3) 4/12 | 43/72 (60%) | NR (17.96–43.11) | OS; DFS | P/P; P/P | Yes | Cox | 7 |
Lin et al. 2017 [21] | China | 127 | HCC | ac | IHC (M, MAB2617, Billerica, 1:100) | NR | C | (3 * 4) 4/12 | 103/127 (81%) | 22 (1–94) | OS | P/P | Yes | Cox | 8 |
Ning et al. 2017 [22] | China | 100 | OSS | Sarcoma | IHC (R, Millipore, 1:150) | PBS | N | (3 * 4) 4.56/12 | 51/100 (51%) | 29.82 (5.26–38.89) | OS; DFS | P/P; P/P | Yes | Cox | 7 |
Ou et al. 2016 [23] | China | 188 | Glioma | Carcinoma | IHC (1:100) | NR | NR | 4/12 | 132/188 (70%) | NR (0–39) | OS | P/P | Yes | Cox | 8 |
Ren et al. 2014 [24] | China | 113 | sEOC | scc | IHC (R, Dako, 1:2000) | PBS | NR | (4 * 4) 12/16 | 91/113 (80%) | NR | OS; PFS | N/NS; N/N | Yes | KM-plot | 6 |
Shen et al. 2012 [25] | China | 40 | GC | ac | WB (R, ab74030, Abcam, 1:600) | actin | NR | Ratio: K2/actin > 2 | 22/40 (55%) | 37.1 (5–77) | OS; PFS | P/NS; P/P | Yes | Cox | 8 |
Li et al. 2017 [26] | China | 109 | ccRCC | ac | IHC (M, Millipore) | NT | C | 50% | 70/109 (64%) | 69 (0.94–82) | OS | P/NS | Yes | Cox | 7 |
Yan et al. 2016 [27] | China | 336 | ccRCC | ac | IHC (M, ab117962, Abcam, 1:100) | NR | NR | (3 * 3) 4/9 | 199/336 (59%) | NR (10–60) | OS; DFS | −/P; −/P | Yes | Cox | 7 |
Study (Author and year) | n | Age (years or numbers): [mean or median (range)] (cut-off: low/high) | Sex (M/F) | Histological differentiation (I/II/III) | Tumor size (cm) (cut-off) (low/high) | Tumor category (grade) | Lymphatic invasion (∓) | Vascular invasion (low/high) | Metastasis (∓) | Staging method | Stage (cut-off) | Other therapy (no/yes) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Yoshida et al. 2017 (I) [14] | 79 | 65 (mean) (41–85) (65):39/40 | 51/28 | 9/63/7 | NR | NR | 19/60 | 32/47 | NR | NR | NR | C: 9/70 R: 68/11 |
Zhan et al. 2015 [15] | 31 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
Mahawithitwong et al. 2013 [16] | 95 | 65 (mean) (36–86) (65): 52/43 | 58/37 | 10/33/52 | NR | (T1/2/3/4) 9/3/82/1 | 34/61* | 38/57 | NR | UICC | NR | C: 10/85 R: 78/17 |
Cao et al. 2015 (II) [17] | 110 | (58): 55/55 | 80/30 | 33/67/10 | (3, 5) 32/45/11 | (T1, 2/3, 4) 7/103 | 57/53 | NR | NR | TNM | (IIB/IIIA) 59/51 | 99/12 |
Cao et al. 2015 (III)[17] | 147 | (58): 79/68 | 113/34 | 23/109/15 | (3, 5) 38/71/36 | (T1, 2/3, 4) 20/127 | 64/83 | NR | NR | TNM | (IIB/IIIA) 70/77 | 104/43 |
Wu et al. 2017 [18] | 203 | (65): 109/94 | 165/38 | (Low/high) 96/107* | (3) 140/63 | NR | NR | NR | NR | TNM | (I/II) 8/115* | NR |
Papachristou et al. 2008 [19] | 60 | 54 (mean) (21–85) | 34/26 | 20/29/11* | (8) 23/37 | NR | NR | NR | NR | NR | NR | NR |
Ge et al. 2015 [20] | 72 | (53): 35/37 | 60/12 | NR | (5) 29/43* | NR | NR | Cap: 44/28* Mic: 49/23* | NR | TNM | (II/III) 41/31 | NR |
Lin et al. 2017 [21] | 127 | (60): 111/16 | 17/110 | NR | (3) 10/117 | NR | NR | Cap: 40/87 Mic: 66/61* | 9/115* | NR | (II/III) 11/116 | NR |
Ning et al. 2017 [22] | 100 | (18): 40/60 | 68/32 | (Low/high) 15/85* | NR | NR | NR | NR | 60/40* | NR | NR | RC: 50/50* |
Ou et al. 2016 [23] | 188 | 39 (mean) (39): 98/90* | 103/85 | NR | NR | NR | NR | NR | NR | NR | (II/III) 85/103* | NR |
Ren et al. 2014 [24] | 113 | (50): 28/85* | −/113 | (Low/high) 26/87* | NR | NR | NR | NR | 49/34 | FIGO | (I/II/III/IV) 9/13/73/10 | RC: 21/68 |
Shen et al. 2012 [25] | 40 | 67 (mean) (47–93) (60): 14/26 | 30/10 | 4/8/28 | NR | (T1, 2/3, 4) 8/32* | N1/2/3 21/10/9* | NR | 37/3 | Pathologic | (II/III) 8/32* | NR |
Li et al. 2017 [26] | 109 | (60):62/47 | 67/42 | 36/41/32* | NR | (Tx/1/2/34) 4/68/20/17 | Nx/0/1 2/99/8* | NR | NR | AJCC | (II/III) 70/39 | NR |
Yan et al. 2016 [27] | 336 | (65):177/159 | 240/96 | NR | (4) 176/160 | (T1, 2/3, 4) 167/169 | 202/134 | NR | 269/67* | TNM | (II/III) 124/212* | NR |
Correlation between Kindlin-2 expression and survival outcomes of solid tumors
Outcome group | Subgroup | No. of studies | No. of patients | Model | Pooled HR (95% CI) | P value of pooled HR | Heterogeneity | P value of meta-regression | |
---|---|---|---|---|---|---|---|---|---|
I2 (%) | P value | ||||||||
Overall | |||||||||
OS | Overall | 16 | 1869 | Fixed | 1.6612 [1.4400; 1.9164] | < 0.0001 | 36.3 | 0.0729 | – |
DFS/RFS/PFS | 11 | 1374 | Random | 1.7309 [1.1643; 2.5733] | 0.0067 | 76.9 | < 0.0001 | ||
Sample size | |||||||||
OS | ≥ 100 | 9 | 1433 | Random | 1.6074 [1.2435; 2.0777] | 0.0003 | 52.5 | 0.03 | 0.3455 |
< 100 | 7 | 436 | Fixed | 1.9081 [1.3873; 2.6245] | 0.0001 | 0.0 | 0.45 | ||
DFS/RFS/PFS | ≥ 100 | 6 | 1009 | Random | 1.3943 [0.8759; 2.2194] | 0.1611 | 70.7 | < 0.01 | 0.2277 |
< 100 | 5 | 365 | Random | 2.2280 [1.1574; 4.2886] | 0.0165 | 78.0 | < 0.01 | ||
Tumor type (from which system) | |||||||||
OS | Digestive | 9 | 780 | Fixed | 1.7955 [1.4224; 2.2664] | < 0.0001 | 0.0 | 0.79 | 0.5000 |
Non-digestive | 7 | 1089 | Random | 1.6305 [1.1236; 2.3662] | 0.0101 | 67.0 | < 0.01 | ||
DFS/RFS/PFS | Digest | 7 | 622 | Random | 2.0137 [1.2856; 3.1542] | 0.0022 | 72.2 | < 0.01 | 0.3149 |
Non-digestive | 4 | 752 | Random | 1.3101 [0.5547; 3.0945] | 0.5378 | 81.9 | < 0.01 | ||
Sample type (from which tissue) | |||||||||
OS | Cancer | 13 | 1492 | Random | 1.7897 [1.3855; 2.3118] | < 0.0001 | 46.1 | 0.03 | 0.5741 |
Stroma | 3 | 377 | Fixed | 1.5830 [1.1958; 2.0957] | 0.0013 | 0.0 | 0.57 | ||
DFS/RFS/PFS | Cancer | 8 | 997 | Random | 1.8358 [1.0668; 3.1589] | 0.0283 | 83.4 | < 0.01 | 0.6650 |
Stroma | 3 | 377 | Fixed | 1.5566 [1.0726; 2.2590] | 0.0199 | 0.0 | 0.74 | ||
Max follow-up time (months) | |||||||||
OS | ≥ 60 | 13 | 1509 | Random | 1.6442 [1.3212; 2.0462] | 0.0207 | 31.7 | 0.13 | 0.4370 |
< 60 | 3 | 360 | Random | 2.4020 [1.1431; 5.0471] | < 0.0001 | 66.3 | 0.05 | ||
DFS/RFS/PFS | ≥ 60 | 9 | 1202 | Random | 1.4740 [0.9864; 2.2028] | 0.0583 | 76.7 | < 0.01 | 0.0258** |
< 60 | 2 | 172 | Fixed | 4.9891 [2.4072; 10.3405] | < 0.0001 | 0.0 | 0.53 | ||
HR extraction | |||||||||
OS | COX | 11 | 1527 | Fixed | 1.7024 [1.4600; 1.9851] | < 0.0001 | 0.0 | 0.61 | 0.4737 |
Non-COX | 5 | 342 | Random | 1.6093 [0.7542; 3.4340] | 0.2185* | 72.7 | < 0.01 | ||
DFS/RFS/PFS | COX | 8 | 1103 | Random | 2.2266 [1.5122; 3.2785] | < 0.0001 | 72.1 | < 0.01 | 0.0085** |
Non-COX | 3 | 271 | Random | 0.7158 [0.2982; 1.7182] | 0.4542* | 66.7 | 0.05 | ||
NOS score | |||||||||
OS | ≥ 8 | 6 | 553 | Fixed | 1.6820 [1.3178; 2.1470] | < 0.0001 | 0.0 | 0.64 | 0.6371 |
< 8 | 10 | 1316 | Random | 1.6701 [1.2539; 2.2243] | 0.0005 | 55.3 | 0.02 | ||
DFS/RFS/PFS | ≥ 8 | 3 | 198 | Random | 1.9211 [0.6133; 6.0179] | 0.2624* | 86.8 | < 0.01 | 0.6479 |
< 8 | 8 | 1176 | Random | 1.6244 [1.0899; 2.4211] | 0.0172 | 69.8 | < 0.01 |